Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Corvus Pharmaceuticals (NASDAQ: CRVS) will present a corporate overview and hold one-on-one investor meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40pm ET.

According to the company, the event is virtual and a webcast will be available live and for 90 days via the investor relations section of Corvus' website.

News Market Reaction – CRVS

+3.54%

6 alerts

+3.54% Session close to close

+7.3% Peak Tracked

-6.0% Trough Tracked

$1.45B Market Cap

0.4x Rel. Volume

In the Feb 24 session, CRVS gained 3.54%, reflecting a moderate positive market reaction. Argus tracked a peak move of +7.3% during that session. Argus tracked a trough of -6.0% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement outlines Corvus presenting a corporate overview at the Oppenheimer conference on F...

Analysis

This announcement outlines Corvus presenting a corporate overview at the Oppenheimer conference on February 26, 2026, with a webcast available for 90 days. It follows recent weeks marked by major financing transactions and positive Phase 1 data for soquelitinib. Investors evaluating this news in context may focus on how management communicates trial plans, cash usage, and timelines during the presentation, and may watch for subsequent clinical or regulatory updates that go beyond this scheduling notice.

Key Figures

Conference edition: 36th Annual Presentation time: 2:40pm ET Webcast availability: 90 days

3 metrics

Conference edition 36th Annual Oppenheimer Healthcare Life Sciences Conference

Presentation time 2:40pm ET Scheduled on Thursday, February 26, 2026

Webcast availability 90 days Replay period following the live presentation

Historical Context

5 past events · Latest: Jan 23 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 23	Offering closed	Negative	-8.3%	Closing of upsized common stock offering with full underwriter option exercise.
Jan 21	Offering priced	Negative	+3.5%	Pricing of upsized common stock offering at a fixed per-share price.
Jan 20	Offering proposed	Negative	+166.0%	Announcement of proposed common stock and pre-funded warrant offering.
Jan 20	Clinical data update	Positive	+166.0%	Positive Phase 1 soquelitinib results in atopic dermatitis cohort 4.
Jan 16	Data release timing	Neutral	+166.0%	Scheduling announcement for upcoming Phase 1 cohort 4 data release.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent price action shows large upside reactions to positive clinical data and initial offering announcements, but weakness on follow-up offering closing, indicating sensitivity to both clinical milestones and dilution events.

Recent Company History

Over the last weeks, Corvus has combined major financing activity with clinical progress. On Jan 20, it announced positive Phase 1 soquelitinib data and a proposed $150M equity and warrant offering, followed by detailed Phase 1 results and financing terms in multiple 424B5 and 8-K filings. Subsequent news on pricing and closing of the upsized common stock offering around $22.15 per share highlighted dilution but also extended cash runway for Phase 3 lymphoma and Phase 2 dermatology/asthma trials. Today’s conference appearance announcement is a routine investor-relations update against that backdrop.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at Oppenheimer 36th Annual Healthcare Life Sciences Conference which is being held virtually. The presentation will be on Thursday, February 26, 2026 at 2:40pm ET.

A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registration Phase 3 clinical trial for relapsed/refractory PTCL and in a Phase 1 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com  

MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750

FAQ

When will Corvus Pharmaceuticals (CRVS) present at the Oppenheimer 2026 conference?

Corvus will present on Thursday, February 26, 2026 at 2:40pm ET. According to the company, the presentation is part of the Oppenheimer 36th Annual Healthcare Life Sciences Conference and will be delivered virtually by members of Corvus' leadership team.

How can investors watch the CRVS presentation at Oppenheimer 36th Annual Healthcare Life Sciences Conference?

Investors can view the presentation via a live webcast on the company's investor relations website. According to the company, the webcast will also remain available for 90 days following the live event for on-demand viewing.

Will Corvus (CRVS) hold one-on-one investor meetings at the Oppenheimer conference?

Yes, Corvus leadership will conduct one-on-one meetings with investors during the conference. According to the company, these meetings accompany the corporate overview presentation and will be held virtually as part of the event schedule.

How long will the CRVS webcast be available after the February 26, 2026 presentation?

The webcast will be available for 90 days following the live presentation. According to the company, investors can access the on-demand recording via the investor relations section of Corvus' website during that 90-day period.

Where on Corvus' website can I find the Oppenheimer presentation webcast for CRVS?

The webcast will be posted in the investor relations section of Corvus' website. According to the company, the live stream and the on-demand recording for 90 days will be accessible from that investor relations page.

What will Corvus (CRVS) cover during its Oppenheimer conference presentation on February 26, 2026?

Corvus will present a corporate overview and discuss recent company developments. According to the company, members of its leadership team will deliver the overview and be available for one-on-one investor meetings during the virtual conference.